Utomilumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Utomilumab
Accession Number
DB15113
Description

Utomilumab is under investigation in clinical trial NCT03318900 (T Cell Immunotherapy for Advanced Ovarian Cancer).

Type
Biotech
Groups
Investigational
Purchasing individual compounds or compound libraries for your research?
Learn More
Synonyms
  • PF-05082566

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Utomilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Utomilumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Utomilumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Utomilumab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Utomilumab.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Utomilumab.
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Utomilumab.
Asfotase alfaThe risk or severity of adverse effects can be increased when Asfotase alfa is combined with Utomilumab.
AtezolizumabThe risk or severity of adverse effects can be increased when Atezolizumab is combined with Utomilumab.
AtoltivimabThe risk or severity of adverse effects can be increased when Utomilumab is combined with Atoltivimab.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
6YY8O697VF
CAS number
1417318-27-4

References

General References
Not Available
Wikipedia
CD137

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentDiffuse Large B-Cell Lymphoma (DLBCL)1
2Active Not RecruitingTreatmentMalignant Neoplasms of Ill-defined Secondary and Unspecified Sites / Malignant Neoplasms of Lip Oral Cavity and Pharynx / Oropharyngeal Cancers1
2RecruitingTreatmentBreast Cancer1
2RecruitingTreatmentCancer, Advanced1
2RecruitingTreatmentInvasive Breast Carcinoma / Recurrent Breast Carcinoma / Stage III Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer / Triple-Negative Breast Carcinoma1
1Active Not RecruitingTreatmentNeoplasms1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentCarcinoma, Squamous Cell of Head and Neck / Diffuse Large B-Cell Lymphoma (DLBCL) / Follicular Lymphoma (FL) / Melanoma, Malignant / Non-Hodgkin's Lymphoma (NHL) / Non-Small Cell Lung Carcinoma (NSCLC) / Renal Cell Adenocarcinoma1
1RecruitingTreatmentCOL6A3 Positive / HLA-A*0201 Positive Cells Present / PRAME Positive / Recurrent Ovarian Carcinoma1
1RecruitingTreatmentFollicular Lymphoma (FL)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on May 20, 2019 08:50 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates